Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.994,37
-0,40%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Dyne Therapeutics Inc (DYN) Dyne Therapeutics Inc (DYN) Notizie

DYN

Dyne Therapeutics (DYN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DYN
DataOraFonteTitoloSimboloCompagnia
24/05/202423:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DYNDyne Therapeutics Inc
24/05/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DYNDyne Therapeutics Inc
22/05/202422:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:DYNDyne Therapeutics Inc
22/05/202402:39GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
21/05/202400:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DYNDyne Therapeutics Inc
20/05/202422:01GlobeNewswire Inc.Dyne Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
20/05/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsNASDAQ:DYNDyne Therapeutics Inc
19/05/202414:00GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETNASDAQ:DYNDyne Therapeutics Inc
02/05/202422:10GlobeNewswire Inc.Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
27/03/202421:05GlobeNewswire Inc.Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerNASDAQ:DYNDyne Therapeutics Inc
27/03/202413:30GlobeNewswire Inc.Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:DYNDyne Therapeutics Inc
25/03/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces CEO TransitionNASDAQ:DYNDyne Therapeutics Inc
13/03/202412:30GlobeNewswire Inc.Dyne Therapeutics to Present at Stifel 2024 Virtual CNS DaysNASDAQ:DYNDyne Therapeutics Inc
05/03/202414:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:DYNDyne Therapeutics Inc
05/03/202413:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DYNDyne Therapeutics Inc
05/03/202413:35Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DYNDyne Therapeutics Inc
05/03/202413:30GlobeNewswire Inc.Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:DYNDyne Therapeutics Inc
14/02/202422:15GlobeNewswire Inc.Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific ConferenceNASDAQ:DYNDyne Therapeutics Inc
14/02/202414:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DYNDyne Therapeutics Inc
01/02/202413:30GlobeNewswire Inc.Dyne Therapeutics to Present at February Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
19/01/202422:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:DYNDyne Therapeutics Inc
11/01/202422:05GlobeNewswire Inc.Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:DYNDyne Therapeutics Inc
05/01/202413:30GlobeNewswire Inc.Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DYNDyne Therapeutics Inc
05/01/202404:46GlobeNewswire Inc.Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common StockNASDAQ:DYNDyne Therapeutics Inc
05/01/202403:19Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:DYNDyne Therapeutics Inc
03/01/202412:30GlobeNewswire Inc.Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle DiseasesNASDAQ:DYNDyne Therapeutics Inc
02/01/202422:05GlobeNewswire Inc.Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER TrialsNASDAQ:DYNDyne Therapeutics Inc
07/11/202313:30GlobeNewswire Inc.Dyne Therapeutics to Present at November Investor ConferencesNASDAQ:DYNDyne Therapeutics Inc
30/10/202312:30GlobeNewswire Inc.Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical MilestonesNASDAQ:DYNDyne Therapeutics Inc
30/10/202312:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DYNDyne Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DYN

La tua Cronologia

EU
EBLRD
Euronext BeNeLux Low Ris...
NASDAQI
GNDX
IPOX Growth Infusion
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network